Trillium Therapeutics Inc.
IMPROVEMENTS IN CD47 BLOCKADE THERAPY BY HDAC INHIBITORS

Abstract:

CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a histone deacetylase (HDAC) inhibitor. The anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinations include SIRP.alpha.Fc as CD47 blockade drug, and one of depsipeptide and romidepsin as HDAC inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.